France raises concerns about heparin made by Dongying Tiandong

By Gareth Macdonald contact

- Last updated on GMT

Related tags: Food and drug administration

France raises concerns about heparin made by Dongying Tiandong
French regulators have raised concerns about heparin made by Chinese supplier Dongying Tiandong Pharmaceutical and called on the EMA to revoke its GMP certificate.

According to a report filed on the European Medicines Agency’s (EMA) EudraGMP database last week​, ANSM inspectors who visited the firm’s facility in Dongying City in December observed 10 deviations from good manufacturing practices (GMP) standards.

The ANSM inspectors said Dongying had used seven batches of out of specification (OOS) crude heparin to make active pharmaceutical ingredients (API) between 2014 and 2015, which they said indicated a “misunderstanding of the basic GMP principles​.”

They also said the firm had not evaluated raw material suppliers sufficiently, specifically that it failed to store delivery documents, test crude heparin or investigate out of specification results identified by a contract analysis laboratory.

The French team also suggested “PCR results of Crude Heparin showing the presence of ruminant DNA received from approved suppliers were manipulated. There was no evidence that the samples retested came from the same batch tested initially​.”

They issued a letter of noncompliance and suggested the EMA revoke Dongying’s GMP certificate – issued by Polish inspectors (GIF-IW-N-4022/68/13) – and called on the consider ordering a recall of heparin products made using the suspect API.

ANSM also called on the EDQM to suspend CEP 2005-258 for Enoxaparin sodium produced by the firm.

According to Dongying's website, the firm passed a US Food and Drug Administration (FDA) inspection in 2013​ and was been cleared to supply heparin sodium and enoxaparin sodium APIs by Mexican authorities in 2014.

The firm did not respond to a request for comment.

Related news

Show more

Related products

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us

Products

View more

Webinars